Developing Next Generation Immunotherapies

Kleo was founded in 2015 by Dr. David Spiegel and Roy Prieb to translate Dr. Spiegel's research in small molecule immunotherapies at Yale University into clinical treatments. Our mission is to develop novel, effective, and safe immunotherapy options to serve patients afflicted by serious diseases.

Kleo holds the worldwide master license to the small molecule immunotherapy technologies patented by Yale and is the recipient of the 2015 Boehringer Ingelheim Innovation Prize. The company is based in New Haven, CT and recently raised its series A financing led by Biohaven Pharmaceuticals.